DOCSLIB.ORG

Monthly Healthcare Review February 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Monthly Healthcare Review February 2017 Monthly Healthcare Review February 2017 IPOs The following table includes the medical devices, biotechnology, pharmaceuticals, and healthcare IPO pricings, filings and withdrawals announced over the previous month. Last Last Financing Financing Company Name HQ Location Description Lead Manager Date Size (Millions) Geumcheon- PCL (SG Cap gu, South Developer of a protein micro-array platform to screen HIV, HCV, HBV and other Korea Investment Technology) (241820) 23-Feb-17 Korea infectious diseases. 12.59 & Securities ABG Sundal Collier, Developer of an anti-cancer drug that has the ability to achieve higher concentrations of Carnegie Stockholm, cancer killing molecules in cancer cells without a corresponding increase in damage to the Investment Bank, Oncopeptides (ONCO) 22-Feb-17 Sweden patient's bone marrow. 73.08 DNB Markets Compiled by: Morgan Reape Source: Pitchbook 1 Monthly Healthcare Review February 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Lead Investor(s) Size Date (Millions) Developer of a genome engineering technology designed to enable high throughput massively-multiplexed CRISPR editing of proteins, pathways Muse Bio 28-Feb-17 Boulder, CO Early Stage VC and genomes. 23.00 Venrock Developer of a single-use endoscopy device that attaches to a standard colonoscope and creates turbulence within the colon using water jets, Motus GI Medical enabling physicians to clean, visualize, diagnose and, if necessary, treat an Technologies 28-Feb-17 Nazareth, Israel Later Stage VC inadequately prepped colon. 30.00 Perceptive Advisors Provider of a non-invasive cardiac magnetic resonance imaging analysis Undisclosed Cardiowise 28-Feb-17 Fayetteville, AR Angel software created for early diagnosis of diseases. 0.23 Investors Developer of an allosteric modulator drug discovery platform created to Herculis Partners, Addex Therapeutics Geneva, offer biopharmaceutical products for the treatment of neurological Undisclosed (ADXN) 28-Feb-17 Switzerland PIPE disorders. 3.00 Investors Developer of single use disposable cartridges to capture stem and progenitor cells from peripheral and umbilical cord blood, bone marrow Undisclosed SynGen 27-Feb-17 Sacramento, CA Later Stage VC and adipose tissue. 3.00 Investors Mauzé-sur-le- PE Growth/ Manufacturer of engineered industrial products, such as stainless steel Pierre Guérin 27-Feb-17 Mignon, France Expansion tanks and bioreactors. Undisclosed Capzanine Pharma Two B 27-Feb-17 Rehovot, Israel Later Stage VC Developer of drugs for the treatment of Parkinson's disease and cancer. 30.00 Israel Biotech Fund Developer of phototherapy beds to cure jaundice in pre-term and full-term Undisclosed Neolight 27-Feb-17 Scottsdale, AZ Angel babies. 1.00 Investors Developer of therapeutics for Duchenne muscular dystrophy and other Undisclosed MyoTherix 27-Feb-17 Union City, CA Early Stage VC muscle disorders. 8.43 Investors Developer of an infectious disease decontamination method using a Georgica Advisors, powdered additive for disinfectants, enabling healthcare workers and New York Angels, Kinnos 27-Feb-17 Brooklyn, NY Seed Round patients to prevent disease outbreak through clothing and other surfaces. 1.00 Venture Well Developer of molecule delivery technology designed to deliver ingredients Undisclosed Illustris Pharmaceuticals 27-Feb-17 Palto Alto, CA Early Stage VC that can permeate tissue structures. 5.00 Investors Developer of a gene editing treatment created to find a cure for Duchenne CureDuchenne Exonics Therapeutics 27-Feb-17 Boston, MA Seed Round muscular dystrophy. 5.00 Ventures Compiled by: Morgan Reape Source: Pitchbook 2 Monthly Healthcare Review February 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Lead Investor(s) Size Date (Millions) Developer of a clinical genome analysis platform that processes genome wide data sets to detect mutations by filtering clinically relevant variants Cambridge, United and deep clinical phenotyping, enabling clinicians to provide actionable Cambridge Congenica 27-Feb-17 Kingdom Early Stage VC interpretation of genetic disease for patients. 9.99 Innovation Capital Xenex Disinfection Developer of a portable device that uses pulsed xenon UV light to kill Services 24-Feb-17 San Antonio, TX Later Stage VC bacteria and viruses in healthcare facility rooms. 38.00 Essex Woodlands Developer of micro-invasive video needle syringes intended to visualize Undisclosed Samark Technology 24-Feb-17 Sarasota, FL Angel orthopedic surgeries. 0.10 Investors Developer of a mobile app and Web interface designed by physicians Undisclosed RapidConnect 24-Feb-17 Raleigh, NC Angel enabling real-time secure communications between the clinical care team. 0.77 Investors UT Horizon Fund, Developer of pharmaceutical products targeting niche, orphan drug Undisclosed Lung Therapeutics 24-Feb-17 Austin, TX Early Stage VC indications for lung injury and disease with an emphasis on fibrosis. 3.48 Investors Serra Ventures, Developer of ultrahigh precision diffraction gratings for X-Ray analysis Undisclosed Inprentus 24-Feb-17 Champaign, IL Early Stage VC and imaging. 0.54 Investors CardioSolv Ablation Developer of a heart simulation software that guides therapies for the Undisclosed Technologies 24-Feb-17 Baltimore, MD Angel treatment of patients with ventricular tachycardia. 0.05 Investors Developer of DNA-based therapeutics using the transformative approach based on delivering a corrected copy of a naturally occurring gene directly to targeted cells designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous Undisclosed Agilis Biotherapeutics 24-Feb-17 Cambridge, MA Early Stage VC system. 12.67 Investors Provider of a non-invasive system to induce therapeutic hypothermia for preservation of tissue following a heart attack, stroke and traumatic brain Western Technology Qool Therapeutics 23-Feb-17 Menlo Park, CA Early Stage VC injury. 6.70 Investment Developer of novel targeted alpha therapeutics for chemotherapy resistant cancers created to leverage radioactivity in relatively low doses to attack Johnson & Johnson Fusion Pharmaceuticals 23-Feb-17 Hamilton, Canada Early Stage VC cancer cells. 25.00 Innovation Compiled by: Morgan Reape Source: Pitchbook 3 Monthly Healthcare Review February 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally placed private equity financings for private and public medical devices, biotechnology, pharmaceuticals, and healthcare companies announced over the previous month. Last Last Financing Company Name Financing HQ Location Round Description Lead Investor(s) Size Date (Millions) Provider of known agricultural biotechnologies such as tissue culture, Intuitive Private cryopreservation, genomics, and marker-assisted breeding to enable Equity, Salveo Front Range cannabis cultivators to improve their yields, reduce disease, and create Capital, Sand Hill Biosciences 23-Feb-17 Boulder, CO Seed Round novel strains. 1.50 Angels Ballast Point Ventures, Developer of medical devices to treat osteoarthritis and apply therapeutic Undisclosed Theragen 22-Feb-17 Manassas, VA Early Stage VC energy technologies for healing and pain relief. 9.14 Investors Developer of small molecule drugs that induce an organized program of cellular death, enabling cancer patients to restore the body's natural defense mechanism and prevent the proliferation of potentially cancerous Topspin Ventures, PMV Pharmaceuticals 22-Feb-17 Cranbury, NJ Early Stage VC cells. 73.73 Euclidean Capital Developer of detection devices providing a measure of the kidney's function or glomerular filtration rate in 15 to 30 minutes, enabling hospitals, cardiac catheterization labs and physician to treat acute kidney Undisclosed PharmacoPhotonics 22-Feb-17 Carmel, IN Angel injuries and chronic kidney diseases. 3.00 Investors Undisclosed Oncternal Therapeutics 22-Feb-17 San Diego, CA Early Stage VC Developer of novel therapies for both rare and common cancers. 18.40 Investors The company uses deep learning technology for drug discovery and drug re-purposing for aging and age-related diseases, allowing for the identification of molecules that may be effective against a variety of cancers as well as metabolic, cardiovascular and central nervous system Undisclosed InSilico Medicine 22-Feb-17 Baltimore, MD Early Stage VC diseases. 10.00 Investors Provider of a treatment designed to translate state-of-the-art science into novel medicines for the treatment of cancer and other diseases of gene Imago BioSciences 22-Feb-17 San Francisco, CA Early Stage VC expression. 40.50 Clarus Ventures Petaling Jaya, Provider of an integrated online ecosystem for local and overseas health Undisclosed BookDoc 22-Feb-17 Malaysia Seed Round travelers. 2.00 Investors Compiled by: Morgan Reape Source: Pitchbook 4 Monthly Healthcare Review February 2017 Private Equity Placements and Venture Capital Rounds The following table includes institutionally
Load more

Recommended publications
  • Chaotic Descriptor Table
    Castle Oldskull Supplement CDT1: Chaotic Descriptor Table These ideas would require a few hours’ the players back to the temple of the more development to become truly useful, serpent people, I decide that she has some but I like the direction that things are going backstory. She’s an old jester-bard so I’d probably run with it. Maybe I’d even treasure hunter who got to the island by redesign dungeon level 4 to feature some magical means. This is simply because old gnome vaults and some deep gnome she’s so far from land and trade routes that lore too. I might even tie the whole it’s hard to justify any other reason for her situation to the gnome caves of C. S. Lewis, to be marooned here. She was captured by or the Nome King from L. Frank Baum’s the serpent people, who treated her as Ozma of Oz. Who knows? chattel, but she barely escaped. She’s delirious, trying to keep herself fed while she struggles to remember the command Example #13: word for her magical carpet. Malamhin of the Smooth Brow has some NPC in the Wilderness magical treasures, including a carpet of flying, a sword, some protection from serpents thingies (scrolls, amulets?) and a The PCs land on a deadly magical island of few other cool things. Talking to the PCs the serpent people, which they were meant and seeing their map will slowly bring her to explore years ago and the GM promptly back to her senses … and she wants forgot about it.
    [Show full text]
  • UNIVERSIDADE ESTADUAL DE CAMPINAS Faculdade De Educação Física
    UNIVERSIDADE ESTADUAL DE CAMPINAS Faculdade de Educação Física HÉLIO JOSÉ COELHO JUNIOR FRAILTY: PREVALENCE, ASSOCIATED FACTORS AND TREATMENT THROUGH RESISTANCE TRAINING FRAGILIDADE: PREVALÊNCIA, FATORES ASSOCIADOS E TRATAMENTO ATRAVÉS DO TREINAMENTO DE FORÇA CAMPINAS 2019 HÉLIO JOSÉ COELHO JUNIOR FRAILTY: PREVALENCE, ASSOCIATED FACTORS AND TREATMENT THROUGH RESISTANCE TRAINING FRAGILIDADE: PREVALÊNCIA, FATORES ASSOCIADOS E TRATAMENTO ATRAVÉS DO TREINAMENTO DE FORÇA Thesis presented to the Faculty of Physical Education of the University of Campinas in partial fulfillment of the requirements for the degree of Doctor, in the area of adapted physical activity. Supervisor: MARCO CARLOS UCHIDA Co-supervisor: BRUNO RODRIGUES ESTE TRABALHO CORRESPONDE À VERSÃO FINAL DA TESE DEFENDIDA PELO ALUNO HÉLIO JOSÉ COELHO JUNIOR, E ORIENTADA PELO PROF. DR. MARCO CARLOS UCHIDA CAMPINAS 2019 Comissão Examinadora Marco Carlos Uchida (Presidente) Emanuele Marzetti Reury Frank Pereira Bacurau Eduardo Lusa Cadore Lígia de Moraes Antunes Correa A Ata da defesa com as respectivas assinaturas dos membros encontra-se no SIGA/Sistema de Fluxo de Dissertação/Tese e na Secretaria do Programa da Unidade. AGRADECIMENTOS Prof. Dr. Marco Carlos Uchida. Sensei, há quase 10 anos o senhor me acolheu como um filho e me ajudou na escolha dos caminhos ao longo dessa jornada. Que orgulho em dizer que o senhor é, não só o meu orientador, mas o meu mentor: um pai científico, seja lá o que isso queira dizer. Obrigado por todo o companheirismo e carinho, por ter aceitado dividir comigo momentos em que o senhor podia apenas se abster. Obrigado pelas conversas incansáveis e por me presentear com uma amizade muita sincera, aceitando as minhas limitações.
    [Show full text]
  • Zeus in the Greek Mysteries) and Was Thought of As the Personification of Cyclic Law, the Causal Power of Expansion, and the Angel of Miracles
    Ζεύς The Angel of Cycles and Solutions will help us get back on track. In the old schools this angel was known as Jupiter (Zeus in the Greek Mysteries) and was thought of as the personification of cyclic law, the Causal Power of expansion, and the angel of miracles. Price, John Randolph (2010-11-24). Angels Within Us: A Spiritual Guide to the Twenty-Two Angels That Govern Our Everyday Lives (p. 151). Random House Publishing Group. Kindle Edition. Zeus 1 Zeus For other uses, see Zeus (disambiguation). Zeus God of the sky, lightning, thunder, law, order, justice [1] The Jupiter de Smyrne, discovered in Smyrna in 1680 Abode Mount Olympus Symbol Thunderbolt, eagle, bull, and oak Consort Hera and various others Parents Cronus and Rhea Siblings Hestia, Hades, Hera, Poseidon, Demeter Children Aeacus, Ares, Athena, Apollo, Artemis, Aphrodite, Dardanus, Dionysus, Hebe, Hermes, Heracles, Helen of Troy, Hephaestus, Perseus, Minos, the Muses, the Graces [2] Roman equivalent Jupiter Zeus (Ancient Greek: Ζεύς, Zeús; Modern Greek: Δίας, Días; English pronunciation /ˈzjuːs/[3] or /ˈzuːs/) is the "Father of Gods and men" (πατὴρ ἀνδρῶν τε θεῶν τε, patḕr andrōn te theōn te)[4] who rules the Olympians of Mount Olympus as a father rules the family according to the ancient Greek religion. He is the god of sky and thunder in Greek mythology. Zeus is etymologically cognate with and, under Hellenic influence, became particularly closely identified with Roman Jupiter. Zeus is the child of Cronus and Rhea, and the youngest of his siblings. In most traditions he is married to Hera, although, at the oracle of Dodona, his consort is Dione: according to the Iliad, he is the father of Aphrodite by Dione.[5] He is known for his erotic escapades.
    [Show full text]
  • 2011 Symposium Program
    UNDERGRADUATE SYMPOSIUM FOR SCHOLARLY & CREATIVE WORK SCHEDULE OF EVENTS Tuesday, April 12, 2011 Symposium Judging 9:00 am – 5:00 pm Grand Ballroom at Tutor Campus Center (Judges only – closed to presenters and general public) Wednesday, April 13, 2011 General Presentations, Exhibits, and Displays 11:00 a.m. - 2:00 p.m. Grand Ballroom at Tutor Campus Center Awards Ceremony & Dinner Reception 6:00 p.m. – 7:30 pm Town & Gown ii April 13, 2011 Dear Members of the USC Community: It is my pleasure to welcome you to USC’s 13th Annual Undergraduate Symposium for Scholarly and Creative Work. The Symposium is designed to provide USC undergraduates with the unique opportunity to exhibit and share examples of their significant research, scholarly and creative work with the university community. Although the Symposium is modeled on a professional conference poster session, students may exhibit their work in a variety of ways, such as through posters, art exhibits, and electronic media. All undergraduates are encouraged to participate. An award ceremony recognizing the most outstanding works will take place at the end of the symposium and includes First Prize awards of $1000 and Second Prize awards of $500 in each of the following categories. Arts Humanities Social Sciences Life Sciences Physical Sciences, Mathematics & Engineering A panel of distinguished faculty will judge submissions in each category. After the judging, you are cordially invited to attend the Award Ceremony at Town & Gown at 6:00 p.m. where the winners will be announced. We hope you enjoy USC’s Undergraduate Symposium, which promises to be a highlight of the semester this year and in many years to come.
    [Show full text]
  • Caerus - Opportunity Drawings
    CAERUS - OPPORTUNITY DRAWINGS Caerus, Greek god of opportunity, also called Kairos, was in fact a spirit. He personified the favorable moment which comes and passes by quickly. In Greek there were two words for "time": "chronos", the linear, chronological time, and "kairos", a moment in an indeterminate period when something special can happen. Two fun and fabulous opportunities here for something special to happen to you! Opportunity Drawing Tickets are $50 each for the new iPad, and $20 each for the colorful C Wonder bicycle and its matching accessories - with a maximum of 100 tickets sold per item. R1 The new iPad 64GB – Resolutionary! Estimated Value: $750 Pick up the new iPad and suddenly, it’s clear. You’re actually touching your photos, reading a book, playing the piano. To make that hands-on experience even better, the fundamental elements of the new iPad are even better—the display, the camera, the wireless connection. All of which makes the third-generation iPad capable of so much more than you ever imagined. Courtesy of Marty and John Farris, Ellen Blumstein and Jim Colburn, Sabrina and Jeffrey Fiddelman, and Edie and Rick Roth R2 C Wonder Bicycle and Accessories in striking Mamaroneck Orange Estimated Value: $350 The C. Wonder Bike will have you peddling in comfort and color! With medium-size tires (not too rugged, not too skinny), this all-purpose bike works for urban oases, rural roads - and just about everywhere in between. It features a comfy leather seat, handbrakes, leather handlebars, and a classic kickstand. This package comes with a matching helmet and accessories—all in coordinating colors! Courtesy of Marty and John Farris, Ellen Blumstein and Jim Colburn, Sabrina and Jeffrey Fiddelman, and Edie and Rick Roth ZEUS - LIVE AUCTION Zeus was the supreme ruler of Mount Olympus, renowned for his fiery temperament and emphatic reactions to events that excited his interest.
    [Show full text]
  • Greek Mythology Link (Complete Collection)
    Document belonging to the Greek Mythology Link, a web site created by Carlos Parada, author of Genealogical Guide to Greek Mythology Characters • Places • Topics • Images • Bibliography • Español • PDF Editions About • Copyright © 1997 Carlos Parada and Maicar Förlag. This PDF contains portions of the Greek Mythology Link COMPLETE COLLECTION, version 0906. In this sample most links will not work. THE COMPLETE GREEK MYTHOLOGY LINK COLLECTION (digital edition) includes: 1. Two fully linked, bookmarked, and easy to print PDF files (1809 A4 pages), including: a. The full version of the Genealogical Guide (not on line) and every page-numbered docu- ment detailed in the Contents. b. 119 Charts (genealogical and contextual) and 5 Maps. 2. Thousands of images organized in albums are included in this package. The contents of this sample is copyright © 1997 Carlos Parada and Maicar Förlag. To buy this collection, visit Editions. Greek Mythology Link Contents The Greek Mythology Link is a collection of myths retold by Carlos Parada, author of Genealogical Guide to Greek Mythology, published in 1993 (available at Amazon). The mythical accounts are based exclusively on ancient sources. Address: www.maicar.com About, Email. Copyright © 1997 Carlos Parada and Maicar Förlag. ISBN 978-91-976473-9-7 Contents VIII Divinities 1476 Major Divinities 1477 Page Immortals 1480 I Abbreviations 2 Other deities 1486 II Dictionaries 4 IX Miscellanea Genealogical Guide (6520 entries) 5 Three Main Ancestors 1489 Geographical Reference (1184) 500 Robe & Necklace of
    [Show full text]
  • On Algorithmic Warfare and Humanitarian Violence
    War and Algorithm 16028-0303f-Finalpass-r01.indd 1 9/24/2019 12:03:26 PM OPEN ACCESS The open access publication of this book is made possible by a grant from Riksbankens Jubileumsfond (The Bank of Sweden Tercentenary Foundation) for the Advancement of the Humanities and Social Sciences. 16028-0303f-Finalpass-r01.indd 2 9/24/2019 12:03:26 PM War and Algorithm Edited by Max Liljefors, Gregor Noll, and Daniel Steuer London • New York 16028-0303f-Finalpass-r01.indd 3 9/24/2019 12:03:26 PM Published by Rowman & Littlefield International Ltd 6 Tinworth Street, London, SE11 5AL, United Kingdom www.rowmaninternational.com Rowman & Littlefield International Ltd. is an affiliate of Rowman & Littlefield 4501 Forbes Boulevard, Suite 200, Lanham, Maryland 20706, USA With additional offices in Boulder, New York, Toronto (Canada), and Plymouth (UK) www.rowman.com Selection and editorial matter © Max Liljefors, Gregor Noll, and Daniel Steuer, 2019 Copyright in individual chapters is held by the respective chapter authors. All rights reserved. No part of this book may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without written permission from the publisher, except by a reviewer who may quote passages in a review. British Library Cataloguing in Publication Data A catalogue record for this book is available from the British Library ISBN: HB 9781786613653 PB 9781786613646 Library of Congress Cataloging-in-Publication Data Available ISBN 9781786613653 (cloth : alk. paper) ISBN 9781786613646 (paper : alk. paper) ISBN 9781786613660 (electronic) The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences—Permanence of Paper for Printed Library Materials, ANSI/NISO Z39.48-1992.
    [Show full text]
  • 2015 American Hackney Horse Society Page 1 Listing of Transfers During the Time Period 01/01/2015 - 12/28/2015
    December 28, 2015 American Hackney Horse Society Page 1 Listing of transfers during the time period 01/01/2015 - 12/28/2015 Pony,Date From To City.State A.......................................... Fashion Maven (24878),Mare,12/11/2015....................................................................................Joshua Law..............................................................................................Karen.......................................... Wood ............................................................................LaMoille, IL A.......................................... Promise Honored (25674),Mare,7/13/2015....................................................................................Martha S Hickham.............................................................................................. Ashlyn.......................................... Farms LLC ............................................................................Simpsonville, KY A.......................................... Promise Honored (25674),Mare,12/11/2015.................................................................................... Ashlyn Farms.......................................... LLC ....................................................Richard.......................................... (Rich) Campbell ............................................................................Shelbyville, KY A.......................................... Regal Moment (28118),Mare,3/4/2015....................................................................................William
    [Show full text]
  • Our Relationship with Time and Temporality in Organisational Practice
    Being (on) time – our relationship with time and temporality in organisational practice Birgitte Pedersen Volume 1 Abstract Issue 1 Thinking about time as something separate to us dominates organisational practice1. Identity questions, career plans, hopes and dreams for both the Winter 2017 individual as well as the organisation are built upon a timeline, and tools and models are designed to remove the obstacles into the future. This paper’s aim is to inspire the professional to be aware of the difference Keywords: between chronology and temporality in order to include more temporal before-the-fact, aspects into their organisational work. The right timing, readiness and block view, attention to temporality in language are examples of indicators on the beyond OD, temporal forms, and it all begins by accepting that we are temporality relational, dialogical, ourselves – regardless of whether we are able to articulate or notice the time, temporality, forms appearing right in front of us. Chronos, Kairos Resumé (Danish) Citation Link Organisatorisk praksis i dag er præget af, at vi tænker ”tid” som uafhængigt af alt andet. Vi isolerer ”tid” på en tidslinje, og vi bygger vores spørgsmål, karriereplaner, modeller, håb og drømme for både den enkelte såvel som for organisationen op omkring denne tidslinje. Formålet med denne artikel er at inspirere den fagprofessionelle til at tænke over og skelne mellem ”tid” som kronologi og som temporalitet, så der kan inkluderes flere temporale aspekter i det organisatoriske arbejde. Udover at skabe en opmærksomhed på sprog, parathed og den rette timing, er formålet med artiklen at pege på behovet for den fagprofessionelles indre accept af, at mennesket i sig selv en temporalitet, der former og fortolker tid – uanset om det enkelte menneske er bevidst om det eller ej.
    [Show full text]
  • GRŠKE MITOLOŠKE OSEBE 1. Del – 1 IMMORTALS
    BIOtransfer GRŠKE MITOLOŠKE OSEBE 1. del – 1 IMMORTALS GRŠKE MITOLOŠKE OSEBE 1. del IMMORTALS KAZALO: 1 Immortals 1.1 Olympian deities 2 1.2 Protogenoi (primordial) 3 1.3 Titans 4 1.4 Gigantes (giants) 6 1.5 Personified concepts 7 1.6 Chthonic deities 12 1.7 Sea deities 13 1.8 Sky deities 16 1.9 Rustic deities 19 1.10 Agricultural deities 31 1.11 Deified mortals 32 1.12 Health deities 33 1.13 Other deities 34 1.14 Seznam z merilnimi podatki o BIOtransferu 37 Vir: http://en.wikipedia.org/wiki/Greek_gods Ljubljana, 04.04.2013 Stran 1 od 50 121010_BR_FOTO_grške_mitološke_osebe_1.del BIOtransfer GRŠKE MITOLOŠKE OSEBE 1. del – 1 IMMORTALS 1 IMMORTALS 1.1 OLYMPIAN DEITIES TWELVE OLYMPIANS 1. Aphrodite 2. Apollo 3. Ares 4. Artemis 5. Athena 6. Demeter 7. Dionysus 8. Hades 9. Hephaestus 10. Hera 11. Hermes 12. Hestia 13. Poseidon 14. Zeus Ljubljana, 04.04.2013 Stran 2 od 50 121010_BR_FOTO_grške_mitološke_osebe_1.del BIOtransfer GRŠKE MITOLOŠKE OSEBE 1. del – 1 IMMORTALS 1.2 PROTOGENOI (PRIMORDIAL) 15. Aether 16. Ananke 17. Erebos or Erebus 18. Gaia or Gaea 19. Hemera 20. Chaos 21. Chronos 22. The Nesoi 23. Nyx or Night 24. Uranus 25. The Ourea 26. Phanes 27. Pontus 28. Tartarus 29. Thalassa Ljubljana, 04.04.2013 Stran 3 od 50 121010_BR_FOTO_grške_mitološke_osebe_1.del BIOtransfer GRŠKE MITOLOŠKE OSEBE 1. del – 1 IMMORTALS 1.3 TITANS THE TWELVE TITANS 30. Hyperion 31. Iapetus 32. Coeus 33. Crius 34. Cronus 35. Mnemosyne 36. Oceanus 37. Phoebe 38. Rhea 39. Tethys 40. Theia 41. Themis Ljubljana, 04.04.2013 Stran 4 od 50 121010_BR_FOTO_grške_mitološke_osebe_1.del BIOtransfer GRŠKE MITOLOŠKE OSEBE 1.
    [Show full text]
  • AGM 2018 Oxford in the Civil War News & Events
    THE NEWSLETTER OF THE CROMWELL ASSOCIATION EYE ON IT Current Industry The Protector’s Pen Trends Suscipit, vicis praesent erat feugait epulae, validus indoles duis enim consequat genitus at. Sed, conventio, aliquip accumsan adipiscing augue blandit minim abbas oppeto AGM 2018 Technology Solutions for Non-Profits commov. Volutpat mos at neque nulla erat.Loquor, vulputate meus indoles Aptent nulla aliquip camur ut Enim neo velit adsum odio, Oxford in the obortis dignissim conventio, iaceo, ne secundum, dolus demoveo consequat aptent nisl in voco multo, in commoveo quibus torqueo, acsi roto modo. Feugait in interdico proprius. In consequat asos consequat. Adipsdiscing magna premo tamen erat huic. Occuro civil war obruo quae ingenium tristique elit quae nulla magna. Delenit abdo esse jumentum velit iriure obruo. damnum uxor dolore, ut at praemitto opto vel natu meus. Molior torqueo quia, te huic. Ratis neque ymo, venio pneum. Aptent nulla aliquip camur ut si sudo, opes feugiat iriure capio velit loquor aptent ut erat illum pala damnum pneum. Aptent consequat lorem aptent nisl magna validus. Sino lenis vulputate, Report on AGM and feugiat pneum commodo vel obruo nulla aliquip camur ut consequat jumentum velitan en iriure. Loquor, valetudo ille abbas cogo saluto Cromwell Day 2017 mara genitus. aptent nisl serpo in voco consequat vulputate meus indoles iaceo, ne quod, esse illum, letatio lorem ququadrum lorem ipso. secundum, dolus demoveo conventio. Letalis nibh iustum Enim neo velit adsum odio, multo, in interddfico proprius. In consequat os Cromwell and the transverbero bene, erat vulpu commoveo quibus premo tamen erat Adipiscing magna jumentum velit quadfse nudflla magna. Aptent nulla tate enim esse si sudo erat.
    [Show full text]
  • Qualifying Therapeutic Discovery Project Grants
    Qualifying Therapeutic Discovery Project Grants The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant. The project descriptions below were extracted from the applicant certification forms as submitted. Alabama $3,708,304.65 Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 Molecular Heparan Sulfate Agenta Biotechnologies Delivery in Barrier Membranes $59,614.76 $184,864.48 Inc and Soft Tissue Wound Closure DELIVERY OF GROWTH- AGENTA FACTOR CO-RECEPTOR BIOTECHNOLOGIES HEPARAN SULFATE IN $169,808.39 $6,666.50 INC BONE GRAFT SUBSTITUTES FOR REPAIR BioCryst BCX4208 for Treatment of $244,479.25 Pharmaceuticals Inc Gout BioCryst Peramivir for Treatment of $244,479.25 Pharmaceuticals, Inc Influenza BioCryst Forodesine for Treatment of $244,479.25 Pharmaceuticals, Inc CLL and CTCL BioCryst BCX4161 for Treatment of $86,380.89 Pharmaceuticals, Inc. Hereditary Angioedema JAK Inhibitors for Treatment BioCryst of Psoriasis, Ankylosing $244,479.25 Pharmceuticals, Inc. Spondylitis, & Multiple Sclerosis Disease Diagnostic Panel Diatherix Laboratories, Development Utilizing the $244,479.25 Inc. TEM-PCR Method Grants Grants Applicant Name Project Name Awarded for Awarded for 2009 2010 EGEN-001 in Platinum- EGEN INC $244,479.25 Resistant Ovarian Cancer EGEN, INC. EGEN TheraSilence $244,479.25 Development of an Apparatus iCubate, Inc $244,479.25 for Performing am-PCR Phase 1, Open-label Syudy Evaluting the Safety of PNP Therapeutics Inc $244,479.25 Escalating Doses of Ad/PNP- F-araAMP SER-201 for the treatment of Serina Therapeutics, Inc $244,479.25 colorectal and ovarian cancer Development of an Vaxin Inc.
    [Show full text]